tradingkey.logo

Trinity Biotech PLC

TRIB
查看詳細走勢圖
1.020USD
-0.260-20.31%
收盤 12/24, 13:00美東報價延遲15分鐘
8.46M總市值
虧損本益比TTM

Trinity Biotech PLC

1.020
-0.260-20.31%
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

-20.31%

5天

+10.15%

1月

+15.25%

6月

+45.71%

今年開始到現在

+15.88%

1年

+23.26%

查看詳細走勢圖

TradingKey Trinity Biotech PLC股票評分

單位: USD 更新時間: 2025-12-24

操作建議

Trinity Biotech PLC當前公司基本面數據相對謹慎,增長潛力較大。當前估值合理,在醫療設備與耗材行業排名151/206位。機構持股佔比非常高,中期看,股價處於平穩狀態。近一個月,市場表現一般,但公司基本面和技術面得分較高。目前股價在壓力位和支撐位之間,可以做區間波段操作。

Trinity Biotech PLC評分

相關信息

行業排名
151 / 206
全市場排名
447 / 4562
所屬行業
醫療設備與耗材

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

分析師目標

基於 0 分析師
--
評級
0.000
目標均價
0.00%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

Trinity Biotech PLC亮點

亮點風險
Trinity Biotech plc is a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors. The Company develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market. The products are used to detect infectious diseases and to quantify the level of Hemoglobin A1c and other chemical parameters in serum, plasma and whole blood, and the Company intends to develop a range of biosensor devices and related services, starting with a continuous glucose monitoring product. Its TrinScreen Human Immunodeficiency Virus (HIV) rapid point-of-care test is a high-quality, single-use immunoassays to aid in the diagnosis of HIV. The Uni-Gold range of rapid point-of-care test devices consist of high-quality, single-use immunoassays to aid in the diagnosis of HIV.
業績增長期
公司處於發展階段,最新年度總收入61.55M美元
估值合理
公司最新PE估值-0.20,處於3年歷史合理位
機構加倉
最新機構持股972.36K股,環比增加42.50%
詹姆斯·西蒙斯持倉
明星投資者詹姆斯·西蒙斯持倉,最新持倉171.36K股
活躍度增加
近期活躍度增加,過去20天平均換手率8.62

Trinity Biotech PLC新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

Trinity Biotech PLC簡介

Trinity Biotech plc is a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors. The Company develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market. The products are used to detect infectious diseases and to quantify the level of Hemoglobin A1c and other chemical parameters in serum, plasma and whole blood, and the Company intends to develop a range of biosensor devices and related services, starting with a continuous glucose monitoring product. Its TrinScreen Human Immunodeficiency Virus (HIV) rapid point-of-care test is a high-quality, single-use immunoassays to aid in the diagnosis of HIV. The Uni-Gold range of rapid point-of-care test devices consist of high-quality, single-use immunoassays to aid in the diagnosis of HIV.
公司代碼TRIB
公司Trinity Biotech PLC
CEOGillard (John)
網址https://www.trinitybiotech.com/

常見問題

Trinity Biotech PLC(TRIB)的當前股價是多少?

Trinity Biotech PLC(TRIB)的當前股價是 1.020。

Trinity Biotech PLC 的股票代碼是什麼?

Trinity Biotech PLC的股票代碼是TRIB。

Trinity Biotech PLC股票的52週最高點是多少?

Trinity Biotech PLC股票的52週最高點是3.440。

Trinity Biotech PLC股票的52週最低點是多少?

Trinity Biotech PLC股票的52週最低點是0.480。

Trinity Biotech PLC的市值是多少?

Trinity Biotech PLC的市值是8.46M。

Trinity Biotech PLC的淨利潤是多少?

Trinity Biotech PLC的淨利潤為-31.79M。

現在Trinity Biotech PLC(TRIB)的股票是買入、持有還是賣出?

根據分析師評級,Trinity Biotech PLC(TRIB)的總體評級為--,目標價格為--。

Trinity Biotech PLC(TRIB)股票的每股收益(EPS TTM)是多少

Trinity Biotech PLC(TRIB)股票的每股收益(EPS TTM)是-5.137。
KeyAI